Physicochemical Properties
| Molecular Formula | C6H7NO |
| Molecular Weight | 109.13 |
| Exact Mass | 109.052 |
| CAS # | 100-55-0 |
| PubChem CID | 7510 |
| Appearance | Light yellow to light brown liquid(Density:1.124 g/cm3) |
| Density | 1.1±0.1 g/cm3 |
| Boiling Point | 266.0±0.0 °C at 760 mmHg |
| Melting Point | -7 °C |
| Flash Point | 97.5±20.4 °C |
| Vapour Pressure | 0.0±0.5 mmHg at 25°C |
| Index of Refraction | 1.551 |
| LogP | -0.46 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 8 |
| Complexity | 65.5 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | OCC1=CC=CN=C1 |
| InChi Key | MVQVNTPHUGQQHK-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2 |
| Chemical Name | pyridin-3-ylmethanol |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Heiberg A. Nikotinyl-alkohol som kolesterolsenkende medikament [Nicotinyl alcohol as a cholesterol-lowering agent]. Nord Med. 1969;81(22):698-700. [2]. Gargaun S, et al. A novel method aimed at counteracting the side effects caused by prostaglandin e2 deficiency during non-steroidal anti-inflammatory drug therapy. Antiinflamm Antiallergy Agents Med Chem. 2014;13(2):121-127. |
| Additional Infomation |
3-pyridinemethanol is a member of the class of pyridines that is pyridine which is substituted by a hydroxymethyl group at position 3. It has a role as a vasodilator agent and an antilipemic drug. It is a member of pyridines and an aromatic primary alcohol. 3-Pyridinemethanol has been reported in Crocus sativus and Nicotiana tabacum with data available. Alcohol analog of NICOTINIC ACID which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened GANGRENE. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (916.34 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (22.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (22.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (22.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.1634 mL | 45.8169 mL | 91.6338 mL | |
| 5 mM | 1.8327 mL | 9.1634 mL | 18.3268 mL | |
| 10 mM | 0.9163 mL | 4.5817 mL | 9.1634 mL |